Hongjen Chang

Biography

  Dr. Chang has been a member of our board of directors since 2007. Dr. Chang is the Chief Executive Officer and President of Taiwan Global Biofund, a venture capital fund, as well as the Chairman and Chief Executive Officer of YFY Biotech Management Company, a biotechnology consulting firm. He has held both positions since 2005. Dr. Chang serves as director to several publicly traded companies, including The Excelsior Medical Group, Taigen Biopharmaceuticals Holdings Limited, Mycenax Biotech Inc. and Twi Biotechnology, Inc., all of which are biopharmaceutical companies. Dr. Chang served at the Taiwan Department of Health as Deputy Minister from June 2004 to October 2004, as President and Chief Executive Officer of the Bureau of National Health Insurance from 2001 to 2004, and Director General of the Center of Disease Control from 1999 to 2000.  Dr. Chang received an M.D. from National Yang-Ming Medical College, an M.S. in Public Health from National Taiwan University, and an M.S. of Health Policy and Management from the Harvard School of Public Health.   Dr. Chang has been a member of our board of directors since 2007. Dr. Chang is the Chief Executive Officer and President of Taiwan Global Biofund, a venture capital fund, as well as the Chairman and Chief Executive Officer of YFY Biotech Management Company, a biotechnology consulting firm. He has held both positions since 2005. Dr. Chang serves as director to several publicly traded companies, including The Excelsior Medical Group, Taigen Biopharmaceuticals Holdings Limited, Mycenax Biotech Inc. and Twi Biotechnology, Inc., all of which are biopharmaceutical companies. Dr. Chang served at the Taiwan Department of Health as Deputy Minister from June 2004 to October 2004, as President and Chief Executive Officer of the Bureau of National Health Insurance from 2001 to 2004, and Director General of the Center of Disease Control from 1999 to 2000.  Dr. Chang received an M.D. from National Yang-Ming Medical College, an M.S. in Public Health from National Taiwan University, and an M.S. of Health Policy and Management from the Harvard School of Public Health.

Research Interest

Pharma, Clinical research, Pharmaceutical sciences